Peptide Stacking Principles: How to Combine Compounds Without Losing the Signal
A stack is not a list of compounds. A stack is a schedule, a marker set, and a log structure that together let the user attribute movement on the readout to the compound that produced it. The reason most consumer-side stack discussions collapse into anecdotal noise is not that the compounds do not work, but that the structure underneath them is missing — the timing is improvised, the markers overlap without acknowledgment, and the log records the protocol as a single block rather than as a set of resolvable inputs. The principles below are the procedural rules that make a stack legible after the fact, drawn from the pharmacokinetics of the compounds and from the consumer literature that has accumulated around the common combinations.
The half-life arithmetic comes first
Every stack lives on top of a half-life ladder, and the ladder determines what the cadence of the stack can be without the compounds overlapping in unintended ways. BPC-157 has a serum half-life of roughly half an hour and a tissue residence that the consumer literature reads as much longer through the gastric mucosa pathway; TB-500 has a serum half-life in the same range with a tissue residence that runs into days through the actin-binding fraction; ipamorelin clears in roughly two hours; CJC-1295 without DAC clears in roughly thirty minutes, while the DAC-bound variant carries a half-life measured in days; semaglutide has a half-life of about a week; tirzepatide has a half-life of about five days; GHK-Cu has a serum half-life of roughly an hour with a tissue residence that depends heavily on the formulation. A stack that combines a daily compound with a weekly compound has an inherent cadence mismatch that is fine as long as it is acknowledged in the log, and a stack that combines two daily compounds with overlapping mechanisms has a near-impossible attribution problem unless the timing or the dose is staggered.
The practical rule is that the cadence of the stack is set by the longest-half-life compound, and the shorter-half-life compounds are anchored to that cadence as sub-cycles. A weekly GLP-1 cycle running underneath a daily secretagogue stack is a coherent structure because the GLP-1 cadence is the spine and the secretagogue stack is the daily layer on top. The opposite arrangement — a daily compound treated as the spine and a weekly compound treated as a sub-cycle — tends to lose the cadence of the longer-acting molecule in the noise of the daily routine.
Mechanism contention is the second filter
Two compounds that act on the same receptor or the same downstream node belong to the same mechanism class, and stacking inside a mechanism class is rarely additive in the way the consumer literature implies. Ipamorelin and GHRP-6 are both ghrelin-receptor agonists; running them together does not double the growth-hormone pulse, it competes for the same receptor pool and produces a pulse that is at best modestly larger than either alone with a side-effect profile that is harder to read. CJC-1295 and tesamorelin are both GHRH analogues; the stack adds the same way for the same reason. The clean mechanism stacks are pairs that act on different receptors with downstream convergence — a ghrelin agonist with a GHRH analogue, a GLP-1 agonist with a GIP agonist, a healing peptide with a regenerative peptide that uses a different pathway. The convergence is what makes the stack work; the mechanism difference is what makes the stack readable.
Marker contention is the third filter
Even compounds with different mechanisms can share a marker, and the shared marker is the place where attribution breaks down. IGF-1 is shared by every growth-hormone secretagogue and by exogenous growth hormone itself; weight and body-composition markers are shared by every GLP-1 agonist and by every cycle that affects appetite or metabolic rate; the subjective recovery score is shared by every healing peptide and by every cycle that affects sleep or inflammation. The principle is that a stack should not run two compounds whose primary marker is the same one inside the same cycle window, because the resulting movement on the marker cannot be attributed to either compound in isolation. The fix when the protocol logic does require two same-marker compounds is to run them sequentially — one cycle of compound A with a baseline-and-follow-up draw, then a washout, then one cycle of compound B with its own baseline-and-follow-up draw — rather than concurrently.
Injection cadence and site rotation
The mechanical layer underneath the pharmacology is the injection schedule, and a stack that does not have a coherent injection cadence tends to lose the site rotation pattern first. The convention that works for most multi-compound stacks is to anchor each compound to a fixed day-of-week and a fixed site cluster — the GLP-1 dose to a Sunday-evening abdominal injection, the secretagogue stack to a daily evening deltoid alternation, the healing stack to a morning gluteal alternation — so the log preserves the cadence even when the calendar slips. A floating injection schedule with no anchor produces a stack whose dose timestamps cluster around the user's free hours rather than around the pharmacokinetics, and the cadence becomes uninterpretable within a few weeks.
The log structure that resolves it
A stack log that records each compound as a row with its dose, site, timestamp, and the stack composition at that moment is the structure that makes the stack legible after the fact. The composition column is the field that most spreadsheets miss: a BPC-157 dose recorded on a day when the user is also running TB-500 is a different datapoint from a BPC-157 dose recorded on a day when TB-500 is on washout, even though the BPC-157 row looks identical. The composition column makes the difference visible in the sort. The marker readings sit in their own table, time-stamped against the stack composition at the time of the draw, so a follow-up read is comparable to its baseline only when the composition column matches.
The cycle boundary is still the unit
A stack is bounded by a cycle, and the cycle boundary is what makes the stack a finite object that can be compared across iterations. A stack that runs indefinitely with no defined start, end, or washout is not a stack — it is a maintenance protocol, which is a different category with different log requirements. The principle is that every stack has a published or self-defined length, a planned washout, and a follow-up window for the markers, even when the user's intent is to repeat the same stack on the next cycle. The cycle boundary is what allows the next iteration of the same stack to be read as a comparable replicate rather than as a continuation that has lost its baseline.
What this is not
None of the above is medical advice or a recommendation to combine specific compounds. The principles describe the procedural structure that makes a stack interpretable, not the clinical decision to run a stack at all. Peptide stacks involve prescription and non-prescription compounds in jurisdictions where the regulatory status varies, and the decision to run any combination belongs to the user and a qualified clinician. Peptra does not source peptides, does not endorse particular vendors, and does not provide stack-specific dose recommendations.
The practical summary
A stack is legible when the cadence is set by the longest-half-life compound, when no two compounds inside the same window share a primary mechanism, when no two compounds inside the same window share a primary marker, when the injection schedule has fixed day-and-site anchors, when the log records the stack composition alongside each dose, and when the cycle boundary is defined in advance. A stack that satisfies these constraints can be compared across iterations and read against its own baseline. A stack that does not satisfy them produces a body of dose data that the user cannot retrospectively attribute, regardless of how well the individual compounds work.